Vanguard Group Inc. lifted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,021,906 shares of the medical device company’s stock after purchasing an additional 18,571 shares during the period. Vanguard Group Inc. owned about 10.70% of Tandem Diabetes Care worth $207,708,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. Comerica Bank raised its position in shares of Tandem Diabetes Care by 15.1% during the 4th quarter. Comerica Bank now owns 34,364 shares of the medical device company’s stock worth $1,016,000 after purchasing an additional 4,520 shares during the last quarter. CenterBook Partners LP purchased a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $205,000. Capital International Sarl lifted its position in shares of Tandem Diabetes Care by 5.8% in the fourth quarter. Capital International Sarl now owns 56,242 shares of the medical device company’s stock valued at $1,664,000 after acquiring an additional 3,106 shares in the last quarter. KBC Group NV boosted its stake in shares of Tandem Diabetes Care by 256.1% in the fourth quarter. KBC Group NV now owns 239,944 shares of the medical device company’s stock worth $7,098,000 after acquiring an additional 172,570 shares during the last quarter. Finally, Alberta Investment Management Corp increased its position in shares of Tandem Diabetes Care by 8.7% during the fourth quarter. Alberta Investment Management Corp now owns 262,574 shares of the medical device company’s stock worth $7,767,000 after purchasing an additional 20,996 shares in the last quarter.
Insider Transactions at Tandem Diabetes Care
In related news, Director Dick Allen sold 5,000 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $51.68, for a total value of $258,400.00. Following the sale, the director now owns 24,396 shares in the company, valued at approximately $1,260,785.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.20% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Report on Tandem Diabetes Care
Tandem Diabetes Care Trading Down 0.8 %
NASDAQ TNDM opened at $39.15 on Wednesday. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01. The stock has a market capitalization of $2.53 billion, a P/E ratio of -18.04 and a beta of 1.28. The firm’s 50-day moving average is $44.76 and its two-hundred day moving average is $34.13. Tandem Diabetes Care, Inc. has a 12 month low of $13.82 and a 12 month high of $53.69.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical device company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.17. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The firm had revenue of $191.67 million for the quarter, compared to analyst estimates of $173.06 million. On average, sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -1.71 earnings per share for the current year.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Featured Articles
- Five stocks we like better than Tandem Diabetes Care
- What is the S&P/TSX Index?
- RXO Shares Surge Following New Acquisition Deal
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What Are the FAANG Stocks and Are They Good Investments?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.